Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04496466 · ClinicalTrials.gov registry record
Clinical Characterization Protocol for Severe Infectious Diseases (CCPSEI)
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 702
- Enrollment target
NCT04496466: Completed study, sponsored by Johns Hopkins University.
NCT04496466 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 702 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04496466 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 702 participants
- Enrollment target
Study Summary
This is a standardized protocol for the rapid, coordinated clinical investigation of severe or potentially severe acute infections by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Participants with acute illness suspected to be caused by SARS-CoV-2 (COVID-19) will be enrolled. This protocol has been designed to enable data and biological samples to be prospectively collected and shared rapidly in a globally-harmonized sampling schedule. Multiple independent studies can be easily aggregated, tabulated and analyzed across many different settings globally. The protocol is the product of many years of discussion among international investigators from a wide range of scientific and medical. Recruitment under this protocol has been initiated in response to Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) in 2012-2013, Influenza H7N9 in 2013, viral hemorrhagic fever (Ebolavirus) in 2014, Monkeypox \& MERS-coronavirus in 2018, Tick-borne encephalitis virus (TBEV) in 2019 and COVID-19 in 2020. Participants may be newly identified through healthcare system or public health access, under quarantine, or in isolation care in outpatient or inpatient settings relevant to the Johns Hopkins University School of Medicine. Other locations may adopt this study concurrently, under a deferred review, or cooperatively. The existence of this protocol would ensure a timely, comprehensive epidemiologic and clinical characterization of the initial cases of COVID-19 in a mounting pandemic. The World Health Organization (WHO) recognized the need for standardized data collection for the epidemiology, immunology and clinical characteristics of these novel pathogens, and established the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) network in 2011. At the core of the protocol are a standardized schedule, structure and content of clinical, laboratory and microbiologic data collection, supplemented by domain-specific components (e.g., ac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 702 participants |
| Start Date | 2020-04-09 |
| Est. Completion | 2021-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04496466
The ClinicalTrials.gov registry entry for NCT04496466 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 702 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04496466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04496466 about?
NCT04496466 is a clinical study titled "Clinical Characterization Protocol for Severe Infectious Diseases (CCPSEI)". This is a standardized protocol for the rapid, coordinated clinical investigation of severe or potentially severe acute infections by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Participants with acute illness suspected to be caused by SARS-CoV-2 (COVID-19) will be enrolled. This p...
What is the current status of trial NCT04496466?
This trial is currently completed. The enrollment target is 702 participants. The study started on 2020-04-09. Estimated completion is 2021-10-31.
Who is sponsoring clinical trial NCT04496466?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.